Marixino

Memantine hydrochloride, the active ingredient in Marixino, is a NMDA receptor antagonist presented as an oral formulation for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adult patients, helping to preserve cognitive function and daily living activities.

GNH USA supplies Marixino as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures timely delivery and regulatory compliance across multiple regions.

Memantine hydrochloride is used in the management of Alzheimer’s disease, a neurodegenerative disorder affecting cognition and function.

- Alzheimer's disease (moderate to severe): improves cognition and slows functional decline in affected patients. - Behavioral symptoms in Alzheimer’s disease: may reduce agitation and aggression associated with the condition. - Activities of daily living in Alzheimer’s disease: helps maintain independence in routine tasks for many patients.

Memantine hydrochloride may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Constipation - Fatigue

Serious or Rare Side Effects: - Seizures - Severe allergic reactions (rash, angioedema) - Stevens‑Johnson syndrome

When prescribing memantine hydrochloride, clinicians should consider several precautionary measures to ensure safe use.

- Renal impairment: dose adjustment may be required in patients with reduced kidney function. - History of seizures: monitor closely as the drug can lower seizure threshold. - Cardiovascular disease: use cautiously in patients with uncontrolled hypertension or arrhythmias. - Concurrent NMDA antagonists: avoid combining with other agents that block NMDA receptors. - Pregnancy and lactation: safety has not been established; use only if potential benefit justifies risk. - Store at ambient temperature: keep below 25 °C in the original container, protected from moisture and light.

Memantine hydrochloride can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase neuropsychiatric effects. - Ketamine: combined CNS depression can lead to excessive sedation. - High‑dose aspirin: may enhance risk of hypertension.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: memantine may potentiate blood‑pressure‑lowering effects. - Diuretics: increased risk of dehydration and electrolyte imbalance. - Other central nervous system depressants (e.g., benzodiazepines): may increase dizziness and confusion.